Home / Health / BioAge Eyes Cardio Risk & Eye Disease Breakthrough
BioAge Eyes Cardio Risk & Eye Disease Breakthrough
6 Jun
Summary
- BGE-102, an NLRP3 inhibitor, targets cardiovascular risk and eye disease.
- Phase 1 trial showed significant reduction in hsCRP levels.
- Phase 2 trial is evaluating doses for cardiovascular risk by year-end.
BioAge Labs is making strides with its lead drug candidate, BGE-102, a potential best-in-class NLRP3 inhibitor. The company is focusing development efforts on cardiovascular disease and ophthalmology. Recent Phase 1 data revealed significant biomarker reductions in obese participants with elevated CRP levels, observing an 86% decrease in hsCRP. These findings are particularly noteworthy given their correlation with improved outcomes in prior cardiovascular studies.
Currently, BioAge is conducting a Phase 2 cardiovascular risk trial, evaluating 30 mg, 60 mg, and 90 mg doses, with results expected by the close of 2026. Concurrently, the company plans to initiate a proof-of-concept study for BGE-102 in diabetic macular edema by mid-2026, anticipating data availability by mid-2027. This dual-track development signifies BioAge's commitment to addressing significant unmet needs in cardiometabolic and ophthalmic conditions.
